3 research outputs found
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
A successful structure-based design
of novel cyclic depsipeptides
that selectively target class I HDAC isoforms is described. Compound <b>11</b> has an IC<sub>50</sub> of 2.78 nM for binding to the HDAC1
protein, and the prodrugs <b>12</b> and <b>13</b> also
exhibit promising antiproliferative activities in the nanomolar range
against various cancer cell lines. Compounds <b>12</b> and <b>13</b> show more than 20-fold selectivity toward human cancer
cells over human normal cells in comparison with romidepsin (FK228),
demonstrating low probability of toxic side effects. In addition,
compound <b>13</b> exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145) xenograft
model with no observed toxicity. Thus, prodrug <b>13</b> has
therapeutic potential as a new class of anticancer agent for further
clinical translation
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
A successful structure-based design
of novel cyclic depsipeptides
that selectively target class I HDAC isoforms is described. Compound <b>11</b> has an IC<sub>50</sub> of 2.78 nM for binding to the HDAC1
protein, and the prodrugs <b>12</b> and <b>13</b> also
exhibit promising antiproliferative activities in the nanomolar range
against various cancer cell lines. Compounds <b>12</b> and <b>13</b> show more than 20-fold selectivity toward human cancer
cells over human normal cells in comparison with romidepsin (FK228),
demonstrating low probability of toxic side effects. In addition,
compound <b>13</b> exhibits excellent in vivo anticancer activities in a human prostate carcinoma (Du145) xenograft
model with no observed toxicity. Thus, prodrug <b>13</b> has
therapeutic potential as a new class of anticancer agent for further
clinical translation
Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry
We report the design, synthesis, and biological evaluation
of a
new series of largazole analogues in which a 4-methylthiazoline moiety
was replaced with a triazole and tetrazole ring, respectively. Compound <b>7</b> bearing a tetrazole ring was identified to show much better
selectivity for HDAC1 over HDAC9 than largazole (10-fold). This work
could serve as a foundation for further exploration of selective HDAC
inhibitors using a largazole molecular scaffold